Moderna announces its vaccine against COVID-19 has 94.5% efficacy
The American company Moderna has announced that the vaccine it is developing against the coronavirus has an effectiveness of 94.5 percent, and that it meets the criteria of effectiveness for marketing.
https://www.dw.com/ – In the note, the company states this Monday (16.11.2020) that it is a «great day» in the fight against coronavirus, says that it has met the criteria set out in the protocol to study its effectiveness, and that it will submit the documentation for final approval in the coming days.
The study, known as the COVE study, recruited more than 30,000 participants in the US and has been conducted, says the statement, according to the National Institute of Allergies and Infectious Diseases (NIAID) and the US health institutes, part of the National Institutes of Health (NIH) and the Biomedical Institute.
The results come immediately after similar results from Pfizer and increase confidence that vaccines can help end the pandemic. The two companies have used a novel approach to design their vaccines.
Moderna has developed an «RNA vaccine», which means that part of the genetic code of the coronavirus is injected into the body, allowing the production of enough proteins to train the immune system.
According to the Moderna report, the main endpoint of the study is based on the analysis of confirmed and awarded cases of COVID-19 from two weeks after the second dose of vaccine.
«This first intermediate analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the group of people to whom a placebo was administered, compared to five cases observed in the group that received the vaccine», says the statement.
As a second endpoint, it was included that the 11 severe cases were all developed in the group to which the placebo was given and not the vaccine.
The 95 cases of COVID-19 included 15 older adults (older than 65) and 20 participants who identified themselves as belonging to various communities (including 12 Hispanics or Latinos, 4 Blacks or African Americans, 3 Asian Americans, and 1 multiracial), the company says.
Moderna states that when reviewing the contraindications, it was concluded that «in general, the vaccine was well tolerated» and that most of the «adverse events were of mild or moderate severity», in addition to being of short duration.
Severe events with a frequency greater than or equal to 2% after the first dose included pain at the injection site (2.7%), and after the second dose included fatigue (9.7%), myalgia (8.9%), headache, and redness at the injection site.
In the company’s statement, executive director Stéphane Bancil said. This is a crucial moment in the development of our candidate vaccine COVID-19. Since early January, we have been pursuing this virus with the intention of protecting as many people as possible around the world. All the time we have known that every day is important».
This positive interim analysis from our phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease, “said Stéphane Bancel in a statement.
CP (afp, efe, rtr)
See original article at: https://www.dw.com/
External attacks on companies cause the most expensive losses of cyber-insurance. However, it is the mistakes of employees and technical problems that generate the most casualties by number. [...]
La Línea naviera observó marcada recuperación de los volúmenes transportados [...]
The US government is aware of at least 20 fishing vessels and 35 oil rigs and offshore supply vessels that have been targeted by pirates and armed thieves since January 2018 in the Bay of Campeche, south of the Gulf of Mexico, according to a maritime alert issued between 5 and 7 November this year; currently cancelled. [...]
Beyond the scientific challenges in the development of these drugs, the eventual overcoming of the pandemic involves solving problems in the transport and effective distribution of these. How will this task be done? [...]